The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2
批准号:
9248902
负责人:
YI SUN
金额:
$36.81万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-05-11 至 2021-03-31
关键词:
Adaptor Signaling ProteinAffectApoptosisBindingBiologicalBiological ProcessCUL1 geneCell Culture TechniquesCell Cycle ProgressionCell ProliferationCell SurvivalDNA biosynthesisDataEmbryonic DevelopmentF Box DomainF-Box ProteinsFBXW7 geneFamilyFutureGrowthHumanIn VitroLungLung NeoplasmsMalignant neoplasm of lungMammalian CellMediatingMutationNon-Small-Cell Lung CarcinomaOncogenesOncogenicPatientsPhosphotransferasesProteinsProteomicsRBX1 geneRoleSKP2 geneScaffolding ProteinSignal PathwaySignaling MoleculeSkp1-Cullin-F-Box ProteinsSkp2 ProteinsSpecificityTestingTissuesTumor Suppressor GenesTumor Suppressor Proteinsbeta-Transducin Repeat-Containing Proteinsbiomarker developmentcancer cellgain of functiongenetic regulatory proteinin vivolung tumorigenesismembermouse modelmutantnovelp19(SKP1) Proteinprotein degradationpublic health relevancetargeted biomarkertumortumorigenesisubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): SCF (SKP1-Cullins-F box protein) E3 ubiquitin ligase is the largest family of E3 ligases that promote the ubiquitylation and degradation of various key regulatory proteins, thus controlling many important biological processes, such as apoptosis, cell cycle progression, DNA replication, embryogenesis and tumorigenesis. SCF consists of 4 components, including a scaffold protein cullin-1, an adaptor protein SKP1, a RING protein RBX1 or RBX2 and an F-box protein. The F-box protein with 69 members in mammalian cells is the substrate- recognizing subunit that determines the specificity of SCF E3s. While a variety of protein substrates have been identified by one of well-characterized F-box proteins ßTrCP, FBXW7, or SKP2, very little is known as to whether and how F-box proteins regulate each other. Our preliminary data showed that 1) oncogenic F-box protein TrCP binds to yet a poorly characterized F-box protein FBXW2 to promote its ubiquitylation and degradation; 2) FBXW2 in turn binds to oncogenic F-box protein SKP2 to promote its ubiquitylation and degradation; 3) FBXW2 has tumor suppressive function against lung cancer cells; 4) A number of gain-of- function FBXW2 mutations were found in human non-small cell lung carcinoma tissues; and 5) reversed correlation in expression among β-TrCP, FBXW2 and SKP2 exists in lung cancer tissues, which is associated with patient survival. Although β-TrCP and SKP2 are well-studied F-box proteins with oncogenic activity, whether and how they regulate each other with regard to cell proliferation and survival is totally unknown. The objectives of this proposed study is to understand how FBXW2 mediates and modulates the activity of two well-known oncogenic F-box proteins, β-TrCP and SKP2, and how FBXW2 acts as a novel tumor suppressor in lung tumorigenesis using both in vitro cell culture and in vivo genetically modified mouse models with elucidation of its mechanism of action. The central hypothesis is that three F- box proteins, βTrCP-FBXW2-SKP2 form an oncogene-tumor suppressor-oncogene axis that regulates each other to control cell proliferation and lung tumorigenesis. Three specific aims are proposed to test our central hypothesis by 1) characterizing FBXW2 as a novel substrate of β-TRCP; 2) characterizing FBXW2 as a novel E3 ligase for SKP2 degradation; and 3) characterizing Fbxw2 as a novel tumor suppressor against lung tumorigenesis. Relevance: Successful completion of this proposed study will mechanistically elucidate how three F-box proteins regulate proliferation of lung cancer cells by targeting each other for degradation, and how two oncogenic F-box proteins ß-TrCP and SKP2 talk with each other via a tumor suppressive F-box protein FBXW2, and how FBXW2 acts as a tumor suppressor in the lung, thus elucidating a novel mechanism of lung tumorigenesis and providing attractive targets for future biomarker development in lung cancer management.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis
-
批准号:8602514
-
项目类别:
-
资助金额:$31.3万
-
财政年份:2013
-
负责人:YI SUN
-
依托单位:
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis
-
批准号:8451029
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2013
-
负责人:YI SUN
-
依托单位:
Anti-pancreatic tumorigenesis by inactivation of SAG/RBX2 E3 ubiquitin ligase
-
批准号:8601690
-
项目类别:
-
资助金额:$16.4万
-
财政年份:2013
-
负责人:YI SUN
-
依托单位:
Anti-pancreatic tumorigenesis by inactivation of SAG/RBX2 E3 ubiquitin ligase
-
批准号:8450970
-
项目类别:
-
资助金额:$20.29万
-
财政年份:2013
-
负责人:YI SUN
-
依托单位:
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis
-
批准号:8785658
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2013
-
负责人:YI SUN
-
依托单位:
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis
-
批准号:8478051
-
项目类别:
-
资助金额:$25.19万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis
-
批准号:8677741
-
项目类别:
-
资助金额:$26.0万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target
-
批准号:8625717
-
项目类别:
-
资助金额:$31.3万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target
-
批准号:8447574
-
项目类别:
-
资助金额:$30.33万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis
-
批准号:8842935
-
项目类别:
-
资助金额:$26.8万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target
-
批准号:8054560
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis
-
批准号:8299931
-
项目类别:
-
资助金额:$26.8万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis
-
批准号:8130417
-
项目类别:
-
资助金额:$26.74万
-
财政年份:2011
-
负责人:YI SUN
-
依托单位:
Luciferase-based screening for p53 conformational activators
-
批准号:8011584
-
项目类别:
-
资助金额:$3.86万
-
财政年份:2010
-
负责人:YI SUN
-
依托单位:
Luciferase-based screening for p53 conformational activators
-
批准号:8089367
-
项目类别:
-
资助金额:$3.75万
-
财政年份:2010
-
负责人:YI SUN
-
依托单位:
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis
-
批准号:7145233
-
项目类别:
-
资助金额:$26.97万
-
财政年份:2006
-
负责人:YI SUN
-
依托单位:
Substrates of SAG-SCF E3 ligase regulate hypoxia response
-
批准号:7049006
-
项目类别:
-
资助金额:$14.46万
-
财政年份:2006
-
负责人:YI SUN
-
依托单位:
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis
-
批准号:7645060
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2006
-
负责人:YI SUN
-
依托单位:
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis
-
批准号:7251511
-
项目类别:
-
资助金额:$26.19万
-
财政年份:2006
-
负责人:YI SUN
-
依托单位:
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis
-
批准号:7472518
-
项目类别:
-
资助金额:$26.14万
-
财政年份:2006
-
负责人:YI SUN
-
依托单位:
海外基金